Priscilla Hollander

13.2k total citations · 2 hit papers
96 papers, 6.9k citations indexed

About

Priscilla Hollander is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Molecular Biology. According to data from OpenAlex, Priscilla Hollander has authored 96 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Endocrinology, Diabetes and Metabolism, 32 papers in Pharmacology and 26 papers in Molecular Biology. Recurrent topics in Priscilla Hollander's work include Diabetes Treatment and Management (56 papers), Diabetes Management and Research (48 papers) and Pharmacology and Obesity Treatment (28 papers). Priscilla Hollander is often cited by papers focused on Diabetes Treatment and Management (56 papers), Diabetes Management and Research (48 papers) and Pharmacology and Obesity Treatment (28 papers). Priscilla Hollander collaborates with scholars based in United States, United Kingdom and Belgium. Priscilla Hollander's co-authors include Samuel Klein, Nick Finer, Luc F. Van Gaal, Michael D. Jensen, André Scheen, Louis J. Aronne, Thomas A. Wadden, Julio Rosenstock, Paula M. Hale and Elsie Allen and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Priscilla Hollander

93 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

2013 610 citations Priscilla Hollander, Samuel Klein et al. profile →
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

2006 558 citations André Scheen, Nick Finer et al. The Lancet profile →

Peers

Countries citing papers authored by Priscilla Hollander

Since Specialization

Citations

This map shows the geographic impact of Priscilla Hollander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priscilla Hollander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priscilla Hollander more than expected).

Fields of papers citing papers by Priscilla Hollander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Priscilla Hollander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priscilla Hollander. The network helps show where Priscilla Hollander may publish in the future.

Co-authorship network of co-authors of Priscilla Hollander

This figure shows the co-authorship network connecting the top 25 collaborators of Priscilla Hollander. A scholar is included among the top collaborators of Priscilla Hollander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Priscilla Hollander. Priscilla Hollander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study 2020 ·Diabetes Therapy ·Xuejun Peng, Rajeev Ayyagari, (unknown), Lizheng Shi, Eboni G. Price‐Haywood, Priscilla Hollander, Vivian Fonseca	9
2	Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial 2018 ·Diabetes Obesity and Metabolism ·Priscilla Hollander, (unknown), Raymond L. H. Lam, Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, (unknown), Marc Rendell, Philip Home, Baptist Gallwitz, Julio Rosenstock	10
3	Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial 2018 ·Diabetes Obesity and Metabolism ·Philip Home, Raymond L. H. Lam, (unknown), Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, (unknown), Julio Rosenstock, Priscilla Hollander, Baptist Gallwitz	5
4	Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial 2017 ·Diabetes Care ·Priscilla Hollander, Harold Bays, Julio Rosenstock, Mary Ellen Frustaci, Albert Fung, Frank Vercruysse, Ngozi Erondu	90
5	Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study 2017 ·Diabetes Therapy ·Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory T. Golm, Susan Huyck, Steven G. Terra, James P. Mancuso, Samuel S. Engel, Brett Lauring	88
6	Weight change upon once‐daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin‐naïve individuals with type 2 diabetes: results from the DIET trial 2013 ·Diabetes Obesity and Metabolism ·Kevin D. Niswender, Milivoj Piletič, Henning Andersen, (unknown), Priscilla Hollander	14
7	Insulin degludec allows for flexible daily dosing in type 1 diabetes, providing equal glycaemic control with less nocturnal hypoglycaemia than insulin glargine over 52 weeks 2012 ·Diabetologia ·(unknown), Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, (unknown), Stephen C. Bain, (unknown), (unknown), D. L. Russell-Jones	6
8	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial 2012 ·The Lancet ·Alan J. Garber, Allen B. King, Stefano Del Prato, Séamus Sreenan, Mustafa Kemal Balcı, Manuel Muñoz‐Torres, Julio Rosenstock, Lars Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander	265
9	Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient‐level pooled analysis 2011 ·Diabetes/Metabolism Research and Reviews ·Ajay Chaudhuri, Julio Rosenstock, Andrés Digenio, Luigi Meneghini, Priscilla Hollander, Janet B. McGill, Paresh Dandona, John Ilgenfritz, Matthew C. Riddle	14
10	Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial 2009 ·Diabetes Technology & Therapeutics ·Julio Rosenstock, William T. Cefalu, Priscilla Hollander, Sol S. Klioze, (unknown), William Duggan	32
11	A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes 2009 ·Diabetes Obesity and Metabolism ·Mark Kipnes, Priscilla Hollander, Ken Fujioka, Ira Gantz, Thomas Seck, Ngozi Erondu, Yue Shentu, Kaifeng Lu, S Suryawanshi, (unknown), Amy O. Johnson‐Levonas, Steven B. Heymsfield, Deborah R. Shapiro, Keith D. Kaufman, John M. Amatruda	43
12	Endocannabinoid Blockade for Improving Glycemic Control and Lipids in Patients with Type 2 Diabetes Mellitus 2007 ·The American Journal of Medicine ·Priscilla Hollander	41
13	Basal insulin or premix analogue therapy in type 2 diabetes patients 2007 ·European Journal of Internal Medicine ·Philip Raskin, Priscilla Hollander, Andrew Lewin, Robert A. Gabbay, Bruce W. Bode, Alan J. Garber	51
14	Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA (1c)>= 8%) on monotherapy with metformin or sulfonylureas 2006 ·Diabetologia ·André Scheen, Nick Finer, Mary Ellen Jensen, Priscilla Hollander, L. Van Gaal	1
15	The Editor’s Roundtable: The Metabolic Syndrome 2006 ·The American Journal of Cardiology ·Vincent Friedewald, Scott M. Grundy, Antonio M. Gotto, S.M. Haffner, (unknown), Priscilla Hollander, William C. Roberts	3
16	A 6‐Month Randomized, Placebo‐Controlled, Dose‐Ranging Trial of Topiramate for Weight Loss in Obesity 2003 ·Obesity Research ·George A. Bray, Priscilla Hollander, Samuel Klein, Robert F. Kushner, Brian Levy, M. Fitchet, Barbara H. Perry	263
17	Addition of pramlintide to insulin therapy lowers HbA _1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets 2003 ·Diabetes Obesity and Metabolism ·Priscilla Hollander, Robert E. Ratner, Mark Fineman, S. Strobel, Larry Z. Shen, David Maggs, Orville Kolterman, C. Weyer	47
18	Physical performance in persons with spinal cord injuries after discharge from rehabilitation 1999 ·Medicine & Science in Sports & Exercise ·A.J. Dallmeijer, L.H.V. van der Woude, Priscilla Hollander, E L D Angenot	34
19	Safety Profile of Acarbose, an α-Glucosidase Inhibitor 1992 ·Drugs ·Priscilla Hollander	145
20	A practical guide to using insulin 1989 ·Postgraduate Medicine ·Leanne Mullen, Priscilla Hollander	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact